Another study employed exposureresponse modelling of data from the SUSTAIN trial programme to estimate the impact of switching from liraglutide, dulaglutide or exenatide extended-release to semaglutide
Additionally, patient preference for medications with dual benefits of glucose control and weight management is strengthening demand for GLP-1 therapies across global healthcare systems
As global life expectancy continues to rise, it is anticipated that the prevalence of cataracts would increase, emphasizing the urgent need to develop affordable and accessible pharmacological alternatives for managing this condition [16]
Increased liver stiffness in alcoholic liver disease: differentiating fibrosis from steatohepatitis
These types of formulations typically require stronger positioning around active ingredients, deeper skin penetration claims, and professional credibility
doi: 10.14309/ajg.0000000000000492